127 related articles for article (PubMed ID: 15233204)
1. Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog.
Hofland LJ
J Endocrinol Invest; 2003; 26(8 Suppl):8-13. PubMed ID: 15233204
[No Abstract] [Full Text] [Related]
2. Rationale for treating cancer with somatostatin analogs.
Minuto F; Ferone D; Arvigo M; Barreca A
J Endocrinol Invest; 2003; 26(8 Suppl):117-9. PubMed ID: 15233226
[No Abstract] [Full Text] [Related]
3. [Somatostatin analog].
Muranaka T; Yuki S; Komatsu Y
Nihon Rinsho; 2015 Feb; 73 Suppl 2():286-90. PubMed ID: 25831769
[No Abstract] [Full Text] [Related]
4. Antitumor effects of somatostatin.
Pyronnet S; Bousquet C; Najib S; Azar R; Laklai H; Susini C
Mol Cell Endocrinol; 2008 May; 286(1-2):230-7. PubMed ID: 18359151
[TBL] [Abstract][Full Text] [Related]
5. Role of somatostatin analogs in the management of rare tumors and diseases.
Palmieri G; Montella L
J Endocrinol Invest; 2003; 26(8 Suppl):89-91. PubMed ID: 15233221
[No Abstract] [Full Text] [Related]
6. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
7. Potential indications for somatostatin analogs in Cushing's syndrome.
Arnaldi G; Polenta B; Cardinaletti M; Boscaro M
J Endocrinol Invest; 2005; 28(11 Suppl International):106-10. PubMed ID: 16625858
[TBL] [Abstract][Full Text] [Related]
8. The effects of somatostatin analogs on biochemical parameters in acromegaly.
Liuzzi A; Marzullo P
J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
[No Abstract] [Full Text] [Related]
9. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
10. The role of somatostatin analogs in the control of tumor growth.
Lamberts SW; Reubi JC; Krenning EP
Semin Oncol; 1994 Oct; 21(5 Suppl 13):61-4. PubMed ID: 7992085
[No Abstract] [Full Text] [Related]
11. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).
Oberg K
Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941
[No Abstract] [Full Text] [Related]
12. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin, somatostatin analogs and their clinical use].
Krsek M
Cas Lek Cesk; 2003 Mar; 142(3):134-8; discussion 139. PubMed ID: 12756839
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors and breast cancer.
Cameron Smith M; Orlando C; Serio M; Maggi M
J Endocrinol Invest; 2003; 26(8 Suppl):125-30. PubMed ID: 15233228
[No Abstract] [Full Text] [Related]
15. The role of somatostatin analogs in the management of immunoproliferative disease.
Ferone D; Arvigo M; Semino C; Pivonello R; van Hagen PM; Barreca A; Minuto F
J Endocrinol Invest; 2003; 26(8 Suppl):103-8. PubMed ID: 15233223
[No Abstract] [Full Text] [Related]
16. New insights on SOM230, a universal somatostatin receptor ligand.
Boerlin V; van der Hoek J; Beglinger Ch; Poon KW; Hartmann S; Dutreix C; Kovarik JM; Bruns Ch; Weckbecker G; Lewis I; Schnieper P; Hofland LJ; Lamberts SW
J Endocrinol Invest; 2003; 26(8 Suppl):14-6. PubMed ID: 15233205
[No Abstract] [Full Text] [Related]
17. Involvement of somatostatin receptor subtypes in membrane ion channel modification by somatostatin in pituitary somatotropes.
Yang SK; Chen C
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1221-7. PubMed ID: 17892506
[TBL] [Abstract][Full Text] [Related]
18. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions.
Liu Y
Cancer Lett; 2006 Jul; 239(1):21-6. PubMed ID: 16126334
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
20. Pasireoride (Signifor) for Cushing's disease.
Med Lett Drugs Ther; 2013 May; 55(1416):39-40. PubMed ID: 23669783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
